Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BIIB

Biogen Inc

Mar 20 • 04:00PM ET

141.38

Dollar change -0.05
Percentage change -0.04	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO VO QQQ COWZ SPY IVV VTV XLV VOE

Scroll to Statements

Index	NDX, S&P 500	P/E	12.64	EPS (ttm)	11.18	Insider Own	0.51%	Shs Outstand	145.80M	Perf Week	1.00%
Market Cap	20.69B	Forward P/E	8.99	EPS next Y	15.73	Insider Trans	-1.17%	Shs Float	145.62M	Perf Month	3.44%
Income	1.63B	PEG	-	EPS next Q	3.56	Inst Own	91.04%	Short Float	2.55%	Perf Quarter	-6.05%
Sales	9.27B	P/S	2.23	EPS this Y	-3.32%	Inst Trans	2.18%	Short Ratio	2.37	Perf Half Y	-28.67%
Book/sh	114.65	P/B	1.23	EPS next Y	-1.21%	ROA	5.95%	Short Interest	3.72M	Perf Year	-35.56%
Cash/sh	16.23	P/C	8.71	EPS next 5Y	-0.06%	ROE	10.36%	52W Range	128.51 - 238.00	Perf YTD	-7.55%
Dividend Est.	-	P/FCF	7.60	EPS past 5Y	-18.66%	ROI	7.56%	52W High	-40.60%	Beta	0.04
Dividend TTM	-	Quick Ratio	0.90	Sales past 5Y	-5.94%	Gross Margin	67.37%	52W Low	10.01%	ATR (14)	4.32
Dividend Ex-Date	-	Current Ratio	1.35	EPS Y/Y TTM	39.71%	Oper. Margin	22.49%	RSI (14)	47.34	Volatility	2.56% 3.15%
Employees	7605	Debt/Eq	0.40	Sales Y/Y TTM	-1.60%	Profit Margin	17.61%	Recom	2.11	Target Price	194.25
Option/Short	Yes / Yes	LT Debt/Eq	0.29	EPS Q/Q	6.56%	Payout	0.00%	Rel Volume	0.62	Prev Close	141.43
Sales Surprise	1.93%	EPS Surprise	3.26%	Sales Q/Q	1.66%	Earnings	Feb 12 BMO	Avg Volume	1.57M	Price	141.38
SMA20	-0.98%	SMA50	-1.03%	SMA200	-21.72%	Trades		Volume	971,733	Change	-0.04%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327
Jul-24-23	Reiterated	UBS	Buy	$346 → $335
May-01-23	Upgrade	Guggenheim	Neutral → Buy	$270 → $350

Show Previous Ratings

Today 11:30AM	Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
05:12AM	Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks (StockStory)
Mar-19-25 10:30AM	Biogen Inc. (BIIB): Among the Most Undervalued Biotech Stocks to Invest In (Insider Monkey)
Mar-18-25 07:35AM	Health Canada approves Biogens Skyclarys for Friedreichs ataxia (Pharmaceutical Technology)
Mar-14-25 11:30AM	Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report? (Zacks)
10:08AM	Loading…
10:08AM	Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell? (Investor's Business Daily)
Mar-12-25 08:15AM	A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV (BioPharma Dive)
07:47AM	Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR (Clinical Trials Arena)
Mar-11-25 07:30AM	Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients (GlobeNewswire)
Mar-04-25 01:49PM	Is Eli Lilly Stock A Buy As It Plays Ball With Trump To The Tune Of $27 Billion? (Investor's Business Daily)
12:02PM	Tariffs Send Investors to Safety of Food, Drug and Utility Stocks (The Wall Street Journal)
02:11AM	New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimers approach (Pharma Voice)
Mar-03-25 04:02AM	3 Reasons BIIB is Risky and 1 Stock to Buy Instead (StockStory)
Feb-28-25 08:23AM	The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease (PR Newswire)
Feb-25-25 12:19PM	Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
12:39PM	Loading…
Feb-24-25 12:39PM	NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects (Benzinga)
Feb-22-25 11:47PM	Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts (Insider Monkey)
Feb-19-25 06:55AM	Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment (Pharmaceutical Technology)
Feb-18-25 01:32PM	Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal (Benzinga)
08:00AM	Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments (Business Wire)
07:25AM	Biogen buys rights to Stokes rare epilepsy drug (BioPharma Dive)
Feb-13-25 02:30PM	Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts (Benzinga)
10:43AM	Sage Therapeutics price target lowered to $12 from $14 at Scotiabank (TipRanks)
10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive)
07:33AM	Royalty Pharma pays $250m for rights to Biogens lupus drug (Pharmaceutical Technology)
02:08AM	Biogen Inc (BIIB) Q4 2024 Earnings Call Highlights: Strong EPS Growth Amid Revenue Challenges (GuruFocus.com)
12:04AM	Analyst Report: Biogen Inc. (Morningstar Research)
Feb-12-25 11:30PM	Q4 2024 Biogen Inc Earnings Call (Thomson Reuters StreetEvents)
04:18PM	Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat (Investor's Business Daily)
01:30PM	Biogen (BIIB) Q4 2024 Earnings Call Transcript (Motley Fool)
01:13PM	Loading…
01:13PM	Vertiv, Biogen, Super Micro Computer: Market Minute (Yahoo Finance Video)
10:49AM	Q4 2024 SAGE Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:51AM	Biogen expects 2025 profit decline despite strong Q4 (Yahoo Finance Video)
09:39AM	Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma (Benzinga)
09:30AM	Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:41AM	Biogens (NASDAQ:BIIB) Q4 Sales Top Estimates (StockStory)
06:47AM	Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition (Reuters)
06:45AM	Why Investors Might Hammer Biogen Despite Its Earnings Beat (Investor's Business Daily)
Feb-11-25 04:28PM	5 Struggling Stocks That Might Be Buys (Barrons.com)
01:56PM	What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday? (Benzinga)
09:49AM	Bernstein starts Biogen at market-perform, notes near term uncertainty (Investing.com)
08:01AM	Biogen (BIIB) Reports Earnings Tomorrow: What To Expect (StockStory)
Feb-08-25 09:20AM	Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-07-25 09:15AM	Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
07:32AM	Genentech eyes lupus market for Gazyva with positive Phase III data readout (Pharmaceutical Technology)
Feb-05-25 10:00AM	Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:16AM	Lillys investigational Alzheimers to be investigated in prevention trial (Clinical Trials Arena)
Feb-02-25 08:12AM	Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? (Insider Monkey)
Jan-31-25 06:30AM	Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union (GlobeNewswire)
Jan-29-25 12:10PM	Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-28-25 07:28AM	Sage rejects Biogens $469m takeover bid (Pharmaceutical Technology)
Jan-27-25 12:40PM	Sage rebuffs Biogen bid to take it over (BioPharma Dive)
09:28AM	Sage rejects Biogen's $469 million takeover offer, says offer undervalues company (Reuters)
07:12AM	Eisai and Biogens Leqembi sBLA set for Alzheimers maintenance dosing (Pharmaceutical Technology)
07:05AM	FDA clears monthly dosing of Alzheimers drug Leqembi (BioPharma Dive)
Jan-26-25 06:38PM	US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug (Reuters)
06:33PM	FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
Jan-23-25 12:06PM	Biogens higher dose Spinraza under review by US and EU regulators (Pharmaceutical Technology)
09:46AM	Eli Lilly Stock Has Tumbled 23% Since Its August High. Is It A Buy Or A Sell? (Investor's Business Daily)
07:30AM	FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA (GlobeNewswire)
Jan-22-25 12:03PM	Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk (Yahoo Finance)
Jan-21-25 06:05AM	Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma (The Wall Street Journal)
Jan-15-25 06:52AM	At JPM, Biogen CEO tries to take down the deal temperature (BioPharma Dive)
06:26AM	Federal watchdog cites concerns with FDAs accelerated approval process (BioPharma Dive)
Jan-14-25 06:00PM	Biogen CEO sees no burning need for more acquisitions (Reuters)
09:41AM	Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist (TipRanks)
09:40AM	Biogen bid for Sage does not change narrative, says BMO Capital (TipRanks)
09:04AM	FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi (Benzinga)
08:06AM	Eisai and Biogens subcutaneous Leqembi set for FDA review (Pharmaceutical Technology)
Jan-13-25 07:05PM	FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
03:12PM	Biogen proposes acquisition of partner Sage Therapeutics (Pharmaceutical Technology)
11:57AM	Top Stock Movers Now: Moderna, Macy's, Valero Energy, and More (Investopedia)
09:56AM	Biogen Wants to Buy Its Partner Sage for Almost No Premium (Barrons.com)
09:51AM	Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid (Investopedia)
09:38AM	Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? (Benzinga)
07:24AM	Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen (Barrons.com)
07:07AM	Biogens cold and calculated offer to buy Sage receives a mixed reaction on Wall Street (BioPharma Dive)
Jan-10-25 06:49PM	Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (Business Wire)
06:37PM	Biogen proposes to buy remaining stake in Sage in $442 million deal (Reuters)
09:02AM	Heres Why ClearBridge Growth Strategy Sold Biogen (BIIB) (Insider Monkey)
06:43AM	Pfizers PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets (BioPharma Dive)
06:25AM	Alzheimers Drugs Eyed as Next Big Obesity-Like Opportunity (Bloomberg)
Jan-09-25 08:00AM	Is Eli Lilly Stock A Buy Or A Sell After Its Weight-Loss Drug Scores A Major Victory? (Investor's Business Daily)
Jan-08-25 04:40PM	Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)s Struggles with Alzheimers and MS Challenges? (Insider Monkey)
Jan-04-25 07:45AM	These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024 (Motley Fool)
Jan-02-25 12:03PM	Is Eli Lilly Stock A Buy After FDA Pushes Back On Compounded Knockoffs? (Investor's Business Daily)
09:25AM	Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges (Investing.com)
Jan-01-25 09:40AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
09:37AM	The 5 worst performing stocks on the Nasdaq 100 in 2024 (TheStreet)
Dec-28-24 04:49PM	Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025 (Insider Monkey)
Dec-23-24 05:07AM	Biogen Faces Multiple Analyst Downgrades in December 2024 (GuruFocus.com)
Dec-20-24 09:44AM	BMO cuts rating on Merck and Biogen, on lack of near term catalyst (Investing.com)
Dec-16-24 01:16PM	Stifel downgrades Biogen on slow Alzheimers drug launch, uncertainty ahead (Investing.com)
10:26AM	Netflix, Ford, Biogen: Trending tickers (Yahoo Finance Video)
Dec-13-24 08:00AM	CMS says private Medicare plans cant automatically deny Biogens ALS drug (BioPharma Dive)
Dec-11-24 07:10AM	Biogen reinstated with a Neutral at BofA (TipRanks)
Dec-09-24 01:44PM	Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown (Benzinga)
12:27PM	Biogen cut at Jefferies as '2025 has a tough setup' (Investing.com)
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SHERWIN STEPHEN A	Director	Mar 07 '25	Sale	150.02	8,760	1,314,142	11,318	Mar 10 04:09 PM
STEPHEN A SHERWIN	Director	Mar 07 '25	Proposed Sale	147.37	8,760	1,290,961		Mar 07 04:18 PM
Singhal Priya	Head of Development	Feb 10 '25	Option Exercise	0.00	1,212	0	9,423	Feb 12 05:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10 '25	Option Exercise	0.00	2,272	0	14,725	Feb 12 05:47 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10 '25	Option Exercise	0.00	3,257	0	25,712	Feb 12 05:46 PM
Kramer Robin	Chief Accounting Officer	Feb 10 '25	Option Exercise	0.00	834	0	8,257	Feb 12 05:44 PM
Gregory Ginger	EVP, Human Resources	Feb 10 '25	Option Exercise	0.00	2,159	0	18,232	Feb 12 05:43 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 10 '25	Option Exercise	0.00	2,575	0	37,072	Feb 12 05:42 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10 '25	Option Exercise	0.00	1,515	0	8,998	Feb 12 05:40 PM
Izzar Rachid	Head of Global Product Strat.	Feb 07 '25	Option Exercise	0.00	3,844	0	7,860	Feb 11 09:52 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 07 '25	Option Exercise	0.00	4,551	0	23,171	Feb 10 06:59 PM
Viehbacher Christopher	President and CEO	Feb 07 '25	Option Exercise	0.00	9,008	0	16,008	Feb 10 06:55 PM
Grogan Jane	Head of Research	Feb 07 '25	Option Exercise	0.00	1,385	0	1,876	Feb 10 06:52 PM
Keeney Adam	Head of Corporate Development	Feb 07 '25	Option Exercise	0.00	1,801	0	2,463	Feb 10 06:51 PM
Kramer Robin	Chief Accounting Officer	Feb 07 '25	Option Exercise	0.00	1,491	0	7,667	Feb 10 06:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 07 '25	Option Exercise	0.00	4,042	0	13,056	Feb 10 06:47 PM
Singhal Priya	Head of Development	Feb 07 '25	Option Exercise	0.00	2,216	0	8,892	Feb 10 06:45 PM
Gregory Ginger	EVP, Human Resources	Feb 07 '25	Option Exercise	0.00	3,436	0	16,633	Feb 10 06:44 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 07 '25	Option Exercise	0.00	4,130	0	35,088	Feb 10 06:42 PM
Singhal Priya	Head of Development	Jan 31 '25	Option Exercise	0.00	1,828	0	7,254	Feb 03 06:02 PM
Singhal Priya	Head of Development	Dec 06 '24	Option Exercise	0.00	426	0	5,742	Dec 09 04:57 PM
Singhal Priya	Head of Development	Dec 09 '24	Sale	157.21	110	17,293	5,426	Dec 09 04:57 PM
Kramer Robin	Chief Accounting Officer	Dec 06 '24	Option Exercise	0.00	351	0	6,578	Dec 09 04:56 PM
Singhal Priya	Officer	Dec 09 '24	Proposed Sale	157.21	110	17,293		Dec 09 10:33 AM
Grogan Jane	Head of Research	Nov 01 '24	Option Exercise	0.00	695	0	695	Nov 04 04:39 PM
Singhal Priya	Head of Development	Aug 30 '24	Option Exercise	0.00	1,668	0	6,554	Sep 05 06:00 AM
Singhal Priya	Head of Development	Sep 03 '24	Sale	204.22	431	88,019	5,316	Sep 05 06:00 AM
Singhal Priya	Officer	Sep 03 '24	Proposed Sale	204.22	431	88,019		Sep 03 01:00 PM
Keeney Adam	Head of Corporate Development	May 01 '24	Option Exercise	0.00	938	0	938	May 03 08:00 PM
Singhal Priya	Head of Development	Apr 02 '24	Sale	213.09	93	19,817	4,886	Apr 03 08:24 PM
Murphy Nicole	Head of Pharm Ops and Tech	Apr 01 '24	Option Exercise	0.00	240	0	9,751	Apr 03 08:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIIB

Biogen Inc

Upgrade your FINVIZ experience